|
NanoLogix Inc. Appoints Director of IP and Makes Progress on
Rapid Anthrax Detection |
HUBBARD, Ohio, August 27 /PRNewswire-First Call/ -- NanoLogix,
Inc. (OTC:NNLX - News) is pleased to announce that Chris R.
Novak, Esq. has joined the company as Director of Intellectual
Property. In addition, we wish to announce that major
advances have been made in the rapid detection of Anthrax
utilizing the NanoLogix BioNanoChannel™
Device.
Mr. Novak has
over seven years' experience as an intellectual property counsel
in a wide range of high tech industries including the position
of Corporate Intellectual Property Counsel of IDT (Integrated
Device Technology, Inc.), a NASDAQ 100 semiconductor company
with sales of over $800 million a year. Mr. Novak has a
Bachelor of Science in Mechanical Engineering and a Juris
Doctorate, both awarded by Marquette University. He also
holds a Master of Science Degree in Electrical Engineering from
Cal Poly State University. Mr. Novak is licensed for
practice of law in California, Colorado, and Wisconsin and
United States Patent and Trademark Office (USPTO) and is
preparing for admission to the Ohio Bar. In addition to
his experience as a patent attorney, Mr. Novak worked as an
engineer for high-tech companies for ten years.
"Mr. Novak
will represent NanoLogix as our dedicated intellectual property
counsel and manage the expansion and protection of our
technologies through patents and other methods.
NanoLogix's key asset value is its impressive intellectual
property portfolio" said Vice President of Strategic Partnering,
Dana Allen. "We are pleased to welcome Chris to the
Company in this newly-created role."
"I believe
the revolutionary and practical ideas being developed at
NanoLogix will have a major impact on the biotechnology and
energy fields" said Director of IP Chris Novak, Esq. "We
plan to protect these ideas to the fullest extent, and turn
these ideas into marketplace realities that will sharply
increase revenues."
In another
significant development, NanoLogix has been working on a request
from the United States Department of Defense to explore the
potential of rapid determination of Anthrax spore viability,
utilizing NanoLogix's BioNanoChannel™
(BNC) technology. There appears to be an
opportunity to determine the viability and persistence of
Anthrax spores much faster than current methods due to the
unique rapid culturing aspects of the BNC technology.
"Superb progress has been made in our research efforts
simulating Anthrax spore growth through the use of non-hazardous
spores. This research has the potential to immediately translate
to the ability to conduct rapid Anthrax viability testing" said
CEO Bret Barnhizer. "We have been impressed with the
Department of Defense's dedication to finding the best solution
for the security of our country in the event of a biological
attack. We look forward to making a major contribution in
this area by providing a method by which the government is
able to determine the effectiveness of their decontamination
efforts in hours rather than days."
About
NanoLogix, Inc.
NanoLogix
is an industry innovator in the research, development, and commercialization
of nano-biotechnologies, applications and processes. The Company
has developed and owns or has rights to 31 patents related to
various medical technologies, 5 of which also have hydrogen-generation
aspects. In the past year the Company has filed an additional
28 patent applications for discoveries related to hydrogen bioreactors,
medical testing, and innovative medical treatments potentially
related to leukemia and sepsis. NanoLogix is presently operating
a hydrogen bioreactor at Welch's Food. NanoLogix-developed patents
are used to design and market diagnostic test kits for use in
early detection of the
bacteria present in infectious and noninfectious human diseases
such as tuberculosis, pneumonia, HIV/AIDS, cancer, and cystic
fibrosis. The company also owns a patent for the non-toxic induction
of apoptosis ('cell suicide') for the treatment of cancer. BioNanoChannel
is a Trademark of NanoLogix, Inc. For more information on the
Company, visit www.nanologixinc.com.
This
press release contains statements, which may constitute "forward-
looking statements" within the meaning of the Securities
Act of 1933 and the Securities Exchange
Act of 1934, as amended by the Private Securities Litigation Reform
Act of 1995. Those statements include statements regarding the
intent, belief or current expectations of NanoLogix, Inc., and
members of its management as well as the assumptions on which
such
statements are based. Prospective investors are cautioned that
any such forward-looking statements are not guarantees of future
performance and involve risks and uncertainties, and that actual
results may differ materially from those contemplated by such
forward-looking statements. The Company undertakes no obligation
to update or revise forward-looking statements to reflect changed
assumptions, the occurrence of unanticipated events or changes
to future operating results.
Contact:
Investor Relations
Bret Barnhizer, CEO
Telephone: 330-534-0800
E-mail:
Bret@nanologixinc.com
